Pfiz­er’s gam­ble on a new lease on life for ag­ing silde­nafil fran­chise fiz­zles in PhI­II

Pfiz­er took a Phase III shot at re­pur­pos­ing its old drug silde­nafil as a new com­bi­na­tion ther­a­py for per­sis­tent pul­monary hy­per­ten­sion in in­fants. And failed.

Ap­proved in pill form for erec­tile dys­func­tion (Vi­a­gra) and PAH (Re­va­tio), re­searchers took an IV for­mu­la­tion added to in­haled ni­tric ox­ide in­to a piv­otal tri­al in PPHN for new­borns. The study proved that it was no bet­ter at re­duc­ing treat­ment fail­ure or time on ni­tric ox­ide than ni­tric ox­ide alone.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER